[{"id":"13a5e519-7fde-415b-8dc6-2319ff68e863","acronym":"","url":"https://clinicaltrials.gov/study/NCT02039505","created_at":"2021-03-18T07:53:16.055Z","updated_at":"2024-07-02T16:37:00.195Z","phase":"Phase 3","brief_title":"Phase III Study of MLN0002 (300 mg) in the Treatment of Ulcerative Colitis","source_id_and_acronym":"NCT02039505","lead_sponsor":"Takeda","biomarkers":" TPMT","pipe":" | ","alterations":" TPMT mutation","tags":["TPMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TPMT mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Entyvio (vedolizumab)"],"overall_status":"Completed","enrollment":" Enrollment 292","initiation":"Initiation: 02/04/2014","start_date":" 02/04/2014","primary_txt":" Primary completion: 02/27/2018","primary_completion_date":" 02/27/2018","study_txt":" Completion: 06/28/2018","study_completion_date":" 06/28/2018","last_update_posted":"2019-04-25"},{"id":"5ee44da0-e0f7-495c-9dd8-87d70426087b","acronym":"","url":"https://clinicaltrials.gov/study/NCT02425111","created_at":"2021-03-18T07:53:36.579Z","updated_at":"2024-07-02T16:37:06.918Z","phase":"Phase 3b","brief_title":"Effect of Intravenous (IV) Vedolizumab on Mucosal Healing in Crohn's Disease","source_id_and_acronym":"NCT02425111","lead_sponsor":"Takeda","biomarkers":" TPMT","pipe":"","alterations":" ","tags":["TPMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Entyvio (vedolizumab)"],"overall_status":"Completed","enrollment":" Enrollment 101","initiation":"Initiation: 03/30/2015","start_date":" 03/30/2015","primary_txt":" Primary completion: 06/02/2017","primary_completion_date":" 06/02/2017","study_txt":" Completion: 02/21/2018","study_completion_date":" 02/21/2018","last_update_posted":"2018-09-14"}]